货号:A829627
同义名:
盐酸哌唑嗪
/ Prazosin (hydrochloride); cp-12299-1
Prazosin HCl 是一种选择性 α1-肾上腺素受体拮抗剂,常用于高血压、焦虑及创伤后应激障碍(PTSD)相关神经调控机制研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Adrenergic Receptor ↓ ↑ | α-adrenergic receptor ↓ ↑ | β-adrenergic receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ivabradine HCl | ✔ | 98% | |||||||||||||||||
| Maprotiline HCl | ✔ | 98% | |||||||||||||||||
| Cisatracurium besylate | ✔ | 96% | |||||||||||||||||
| Yohimbine HCI | ✔ | 99+% | |||||||||||||||||
| BMY 7378 |
++
α2C-adrenoceptor, pKi: 6.54 α1D-adrenoceptor, pKi: 5.1 |
+
β1-adrenoceptor, pIC50: 5.1 |
97% | ||||||||||||||||
| Asenapine maleate |
++++
α2A-adrenergic receptor, pKi: 8.9 α2B-adrenergic receptor, pKi: 8.9 |
97% | |||||||||||||||||
| Piribedil |
++
adrenoceptor α2A, pKi: 7.1 adrenoceptor α2C, pKi: 7.2 |
98% | |||||||||||||||||
| Prazosin HCl | ✔ | 95% | |||||||||||||||||
| Silodosin | ✔ | 98% | |||||||||||||||||
| Phenoxybenzamine HCl | ✔ | 98% | |||||||||||||||||
| Labetalol HCl | ✔ | 98+% | |||||||||||||||||
| Naftopidil |
+++
α1D-adrenergic receptor, Ki: 20 nM α1A-adrenergic receptor, Ki: 3.7 nM |
98% | |||||||||||||||||
| Naftopidil 2HCl |
+
α1-adrenergic receptor, IC50: 0.2 μM |
99% | |||||||||||||||||
| Alfuzosin HCl | ✔ | 98% | |||||||||||||||||
| Terazosin HCl | ✔ | 99% | |||||||||||||||||
| Atipamezole | ✔ | 95% | |||||||||||||||||
| Phentolamine methanesulfonate salt | ✔ | 99% | |||||||||||||||||
| Carvedilol | ✔ | 99% | |||||||||||||||||
| Doxazosin mesylate | ✔ | 99% | |||||||||||||||||
| Tolazoline HCl | ✔ | 98% | |||||||||||||||||
| Esmolol HCl | ✔ | 95% | |||||||||||||||||
| Propranolol HCl |
++
β-adrenergic receptor, IC50: 12 nM |
99% | |||||||||||||||||
| Zenidolol HCl |
++++
β2-adrenergic receptor, Ki: 0.7nM β1-adrenergic receptor, Ki: 611nM |
98% | |||||||||||||||||
| Acebutolol HCl | ✔ | 97+% | |||||||||||||||||
| Carteolol HCl | ✔ | 98+% | |||||||||||||||||
| Betaxolol | ✔ | 99% | |||||||||||||||||
| Betaxolol HCl |
+
β1-adrenergic receptor, IC50: 6 μM |
97% | |||||||||||||||||
| Bisoprolol | ✔ | 97% | |||||||||||||||||
| Sotalol HCl | ✔ | 95+% | |||||||||||||||||
| Nebivolol HCl |
+++
β1-adrenoceptor, IC50: 0.8 nM |
99% | |||||||||||||||||
| Metoprolol | ✔ | 98+% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Prazosin Hydrochloride, an a1-adrenoceptor blocker, has shown some promise in treating chronic PTSD (Posttraumatic stress disorder). Treatment of PTSD with prazosin is usually initiated at a dose of 1 mg, with monitoring for hypotension after the first dose. The dose is then gradually increased to maintenance levels of 2-6 mg at night[3]. Prazosin has been shown to be effective in the treatment of PTSD trauma-related nightmares, with low side effect profile and abilities to improve both sleep and reduce trauma nightmares[4]. Prazosin is extensively metabolised by the liver and has high first-pass metabolism and low oral bioavailability. Oral bioavailability of prazosin ranges from 43.5 to 69.3% (mean 56.9%). Prazosin is highly (92 to 97%) bound to human plasma proteins (albumin and alpha 1-acid glycoprotein) and the extent of binding is independent of the plasma concentration of the drug in the range of 20 to 150 ng/mL[5]. |
| Concentration | Treated Time | Description | References | |
| HEK293T cells | 10 μM | 6–8 h | Cell protection | Nat Commun. 2023 Aug 10;14(1):4819. |
| HEK 293T cells | 150 nM | 2 h | To measure the binding of Prazosin to the α1A adrenergic receptor, results showed that Prazosin could competitively bind to the receptor. | J Biol Chem. 2021 Jan-Jun;296:100366. |
| HuH-7R cells | 10 μM | Prazosin inhibits Akt activity by targeting the ligand-binding domain of EphA2, reducing EphA2 Ser897 phosphorylation, thereby inhibiting cell migration and invasion. | Exp Mol Med. 2020 Mar;52(3):497-513. | |
| HuH-7R cells | 10 μM | 0, 2, 4, 6 h | Prazosin induces EphA2 internalization, triggering apoptosis and inhibiting migration and invasion of HuH-7R cells. | Exp Mol Med. 2020 Mar;52(3):497-513. |
| YD-8/CIS | 250 nM | 30 min | To monitor BCRP activity, results showed reduced accumulation of prazosin in YD-8/CIS cells, indicating increased BCRP activity. | Int J Mol Sci. 2019 Jun 21;20(12):3034. |
| YD-9/CIS | 250 nM | 30 min | To monitor BCRP activity, results showed reduced accumulation of prazosin in YD-9/CIS cells, indicating increased BCRP activity. | Int J Mol Sci. 2019 Jun 21;20(12):3034. |
| YD-38/CIS | 250 nM | 30 min | To monitor BCRP activity, results showed reduced accumulation of prazosin in YD-38/CIS cells, indicating increased BCRP activity. | Int J Mol Sci. 2019 Jun 21;20(12):3034. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Subcutaneous xenograft tumor model | Oral | 3 mg/kg | Once daily for 18 days | Prazosin alone or in combination with sorafenib significantly inhibits tumor growth and prolongs the survival of tumor-bearing mice. | Exp Mol Med. 2020 Mar;52(3):497-513. |
| Mice | PTP1B KO mice | Intraperitoneal injection | 2 mg/kg | Once daily for 7 days | To assess the effect of Prazosin on vascular adrenergic reactivity, results showed that Prazosin restored vascular adrenergic reactivity in PTP1B KO mice. | Circulation. 2009 Sep 1;120(9):753-63 |
| Mice | IP3R2−/− mice | Intraperitoneal injection | 1 mg/kg | Single injection, lasting 30 minutes | To evaluate the effect of Prazosin on Ca2+ fluctuations in astrocytes during startle responses in mice. Results showed that Prazosin completely inhibited startle-induced Ca2+ fluctuations in astrocyte somata of WT mice, but did not alter the lack of Ca2+ fluctuations observed in the somata of IP3R2?/? mice. In astrocyte processes, Prazosin selectively inhibited the fast component of the startle-evoked Ca2+ event but had no effect on the late component. | Nat Neurosci. 2015 May;18(5):708-17 |
| C57BL/6 mice | Cocaine-induced conditioned place preference model | Intraperitoneal injection | 1 mg/kg, 2 mg/kg | Single dose, tested 30 minutes after administration | To investigate the effects of Prazosin on cocaine-, stress-, and yohimbine-induced reinstatement. Results showed that Prazosin failed to block reinstatement induced by cocaine, stress, or yohimbine. | Neuropsychopharmacology. 2010 Oct;35(11):2165-78 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01677767 | - | Completed | - | India ... 展开 >> Sir Gangaram Hospital New Delhi, Delhi, India, 110060 Ahmedabad Dialysis Centre Ahmedabad, India, 380005 Excel Center Guwahati, India, 781007 ESIS Hospital; Department of Nephrology Kolkata, India, 600054 Vertex Hospital Mumbai, India, 400083 Apollo Indraprastha Hospitals; Nephrology New Delhi, India, 110076 Aditya Birla Memorial Hospital Pune, India, 411033 收起 << | |
| NCT00687388 | Benign Prostatic Hyperplasia | Phase 4 | Withdrawn(in order to prepare ... 展开 >>a new clinical trial to evaluate with pathological change) 收起 << | - | Korea, Republic of ... 展开 >> Severance Hospital Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 << |
| NCT01030874 | Orthostatic Hypotension ... 展开 >> Falls 收起 << | Not Applicable | Completed | - | United States, Oregon ... 展开 >> VA Portland Health Care System, Portland, OR Portland, Oregon, United States, 97239 收起 << |
[3]Green B. Prazosin in the treatment of PTSD. J Psychiatr Pract. 2014;20(4):253-259
[5]Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1980;5(4):365-376
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.91mL 2.38mL 1.19mL |
23.82mL 4.76mL 2.38mL |
|
| CAS号 | 19237-84-4 |
| 分子式 | C19H22ClN5O4 |
| 分子量 | 419.86 |
| SMILES Code | O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4=CC=CO4.Cl |
| MDL No. | MFCD00058177 |
| 别名 | 盐酸哌唑嗪 ;Prazosin (hydrochloride); cp-12299-1; NSC 292810; Prazosin hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | WFXFYZULCQKPIP-UHFFFAOYSA-N |
| Pubchem ID | 68546 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, room temperature |
| 溶解方案 |
DMSO: 15 mg/mL(35.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1